CIK 0001601830 · Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464099738
- Phone
- (385) 269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-26 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −100,000 | $4.84 | $484K | 954,229 |
| 2025-08-26 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −100,000 | 5,373,034 | ||
| 2025-08-18 | Khan Najat Chief R&D Commercial Officer | Sale | −36,599 | $5.52 | $202K | 668,197 |
| 2025-08-15 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −11,908 | $5.64 | $67K | 811,226 |
| 2025-08-15 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes | −40,390 | $5.64 | $228K | 954,229 |
| 2025-08-15 | Khan Najat Chief R&D Commercial Officer | Shares withheld for taxes | −3,789 | $5.64 | $21K | 704,796 |
| 2025-08-11 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +423,666 | 1,504,919 | ||
| 2025-08-11 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −500,300 | $5.28 | $2.6M | 1,004,619 |
| 2025-08-11 | Gibson Christopher Chief Executive Officer | Gift 10b5-1 | −10,000 | 994,619 | ||
| 2025-08-11 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +100,000 | 100,000 | ||
| 2025-08-11 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −100,000 | $5.28 | $528K | 0 |
| 2025-08-11 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +17,875 | 17,875 | ||
| 2025-08-11 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −17,875 | $5.28 | $94K | 0 |
| 2025-08-11 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −423,666 | 5,473,034 | ||
| 2025-08-11 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −100,000 | 386,000 | ||
| 2025-08-11 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −17,875 | 50,000 | ||
| 2025-07-01 | Li Dean Y Director | Grant or award | +1,949 | 1,236,567 | ||
| 2025-07-01 | Dar Zavain Director | Grant or award | +2,924 | 135,817 | ||
| 2025-06-18 | Borgeson Blake Director | Grant or award | +22,016 | 7,089,863 | ||
| 2025-06-18 | Borgeson Blake Director | Grant or award · Stock Option (Right to Buy) | +44,031 | 44,031 |
Page 8 of 9 · 179 trades